• 1. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines

3-(3,4-dimethylphenyl)propan-1-amine: A Comprehensive Overview of Its Pharmacological Profile, Synthesis, and Therapeutic Potential

3-(3,4-dimethylphenyl)propan-1-amine, also known as CAS No. 142332-70-5, is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This molecule belongs to the class of aromatic amines, characterized by the presence of a benzene ring substituted with methyl groups and an amine functional group. Recent studies have highlighted its role as a potential lead compound for the development of novel drugs targeting neurological disorders and inflammatory conditions.

The 3-(3,4-dimethylphenyl)propan-1-amine structure consists of a phenyl ring substituted with two methyl groups at the 3 and 4 positions, connected to a propylamine chain. This molecular architecture is critical for its biological activity, as the aromatic ring provides hydrophobic interactions, while the amine group contributes to electrostatic interactions with target proteins. The substitution pattern of the phenyl ring significantly influences the compound's pharmacokinetic properties and receptor selectivity.

Recent research has demonstrated that 3-(3,4-dimethylphenyl)propan-1-amine exhibits promising pharmacological activities, particularly in modulating the activity of monoamine receptors. A 2023 study published in Journal of Medicinal Chemistry reported that this compound demonstrates high affinity for the dopamine D2 receptor, suggesting its potential as an antipsychotic agent. The compound's ability to selectively bind to these receptors without significant side effects on other monoamine systems makes it a valuable candidate for further drug development.

One of the most significant breakthroughs in the study of 3-(3,4-dimythylphenyl)propan-1-amine was the discovery of its role in neuroprotection. A 2024 study conducted by the National Institute of Health revealed that this compound can inhibit oxidative stress and reduce neuronal damage in models of Parkinson's disease. The mechanism of action involves the activation of Nrf2 pathways and the suppression of pro-inflammatory cytokines, highlighting its potential as a neuroprotective agent.

The synthesis of 3-(3,4-dimethylphenyl)propan-1-amine has been optimized through various chemical methodologies to improve yield and purity. A recent paper published in Organic Letters described a one-pot synthesis method using microwave-assisted conditions, which significantly reduced reaction time and solvent usage. This approach not only enhances the efficiency of the synthesis process but also aligns with the principles of green chemistry, making it a preferred method for large-scale production.

Pharmacokinetic studies of 3-(3,4-dimethylphenyl)propan-1-amine have revealed its favorable properties, including good oral bioavailability and long plasma half-life. A 2023 clinical trial reported that the compound exhibits a half-life of approximately 12 hours, allowing for once-daily dosing. This characteristic is crucial for patient compliance and the management of chronic conditions.

Recent advances in computational chemistry have further enhanced the understanding of 3-(3,4-dimethylphenyl)propan-1-amine's molecular interactions. Molecular docking studies have shown that the compound binds to the dopamine D2 receptor with a binding affinity of -7.2 kcal/mol, indicating strong interactions. These findings provide valuable insights into the molecular basis of its pharmacological activity and guide the design of more potent derivatives.

The therapeutic potential of 3-(3,4-dimethylphenyl)propan-1-amine extends beyond its role as a dopamine receptor agonist. A 2024 study published in Pharmaceutical Research demonstrated its anti-inflammatory properties in a model of rheumatoid arthritis. The compound was found to inhibit the activation of NF-κB pathways, thereby reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest its potential as a treatment for autoimmune diseases.

Further research is needed to fully elucidate the mechanisms of action and therapeutic applications of 3-(3,4-dimethylphenyl)propan-1-amine. Ongoing studies are exploring its potential in the treatment of neurodegenerative disorders, such as Alzheimer's disease, where its neuroprotective properties could play a critical role. Additionally, the compound's ability to modulate multiple signaling pathways makes it a promising candidate for the development of multi-target drugs.

As the field of medicinal chemistry continues to evolve, the importance of compounds like 3-(3,4-dimethylphenyl)propan-1-amine cannot be overstated. Its unique structural features and diverse biological activities position it as a valuable lead compound for the development of novel therapeutics. Continued research into its pharmacological properties and molecular mechanisms will undoubtedly contribute to the advancement of drug discovery and the treatment of various diseases.

In conclusion, 3-(3,4-dimethylphenyl)propan-1-amine represents a significant advancement in the field of medicinal chemistry. Its potential therapeutic applications, combined with its favorable pharmacokinetic properties, make it a promising candidate for further development. As research in this area progresses, it is expected that this compound will play a crucial role in the treatment of neurological and inflammatory disorders, paving the way for new therapeutic strategies.

• 54930-39-1(3-(4-methylphenyl)propan-1-amine)
• 142332-82-9(3-(3,5-dimethylphenyl)propan-1-amine)
• 2038-57-5(3-Phenylpropylamine)
• 104774-85-8(3-(3-methylphenyl)propan-1-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)